Profile
| Metric | Value |
|---|---|
| Full Name | Eli Lilly and Company |
| Ticker | NYSE: LLY |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | lilly.com |
| Employees | 47,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $1,081.00 | |
| Price, 1D Change | +1.64% | |
| Market Cap | $968B | |
| TTM Dividend Yield | 0.56% | |
| PE Ratio | 53.46 | |
| Beta | 0.64 | |
| Revenue | $45B | |
| Revenue, 1Y Change | +32.00% | |
| EPS | $11.71 | |
| EPS, 1Y Change | +101.91% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $1.50 | |
| Next Ex-Dividend | $1.73 | |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $11.71 | |
| EPS Estimate | $23.68 | |
| EPS Est. Change | +102.18% | |
| Revenue | $45.04B | |
| Revenue Estimate | $63.69B | |
| Revenue Est. Change | +41.41% | |
| Current Price | $1,081.00 | |
| Price Target | - | $1,165.00 |
| Price Tgt. Change | - | +7.77% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.05 | $5.80 | -4.11% | |
| $12.88 | $11.71 | -9.06% | |
| $23.68 | N/A | +102.18% | |
| $32.88 | N/A | +180.71% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $33.67B | $34.12B | +1.36% | |
| $45.15B | $45.04B | -0.23% | |
| $63.69B | N/A | +41.41% | |
| $76.90B | N/A | +70.73% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +35.55% | |
| Price, 3Y | +198.93% | |
| Market Cap, 1Y | +35.17% | |
| Market Cap, 3Y | +181.58% | |
| Revenue, 1Y | +32.00% | |
| Revenue, 3Y | +59.06% | |
| EPS, 1Y | +101.91% | |
| EPS, 3Y | +91.33% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $1,081.00 | |
| SMA 200 | $834.97 | |
| SMA 200 vs Price | -22.76% | |
| SMA 50 | $1,028.06 | |
| SMA 50 vs Price | -4.90% | |
| Beta | 0.64 | |
| ATR | $30.94 | |
| 14-Day RSI | 56.24 | |
| 10-Day Volatility | 35.96% | |
| 1-Year Volatility | 40.77% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $1.50 | |
| Upcoming | $1.73 | |
| Dividend Yield | 0.48% | |
| Total Dividend | $5.20 | |
| Dividends Paid | $4.68B | |
| Payout Ratio | 44.20% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $45.04B | |
| EPS | $11.71 | |
| Gross Profit | $36.62B | |
| Gross Margin | 81.31% | |
| Operating Profit | $17.04B | |
| Operating Margin | 19.14% | |
| Net Income | $10.59B | |
| Net Margin | 23.51% | |
| EBITDA | $18.81B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 2.37 | |
| Current Ratio | 1.15 | |
| Quick Ratio | 0.89 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 10.60 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 53.46 | |
| PS Ratio | 16.28 | |
| PB Ratio | 40.66 | |
| EV/EBITDA | 35.36 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $14.19B | |
| Cash & Equivalents | $3.42B | |
| Total Assets | $78.71B | |
| Current Assets | $32.74B | |
| Total Liabilities | $64.44B | |
| Current Liabilities | $28.38B | |
| Total Debt | $33.64B | |
| Short Term Debt | $5.12B | |
| Accounts Payable | $3.23B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $34.45B | |
| Operating Expenses | $19.58B | |
| Cost Of Goods Sold | $8.42B | |
| SG&A | $0.00 | |
| D&A | $1.77B | |
| Interest Expense | $0.00 | |
| Income Tax | $2.09B |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $8.82B | |
| CFI | -$9.30B | |
| CFF | $1.23B | |
| Capex | $8.40B | |
| Free Cash Flow | $414.30M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| B of A Securities | → | |
| Wells Fargo | → | |
| BMO Capital | → | |
| Guggenheim | → | |
| Morgan Stanley | → | |
| Bernstein | → | |
| Truist Securities | → | |
| JP Morgan | → | |
| Morgan Stanley | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
Screeners with LLY
Data Sources & References
- LLY Official Website www.lilly.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- LLY Profile on Yahoo Finance finance.yahoo.com/quote/LLY
- LLY Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/lly
FAQ
What is the ticker symbol for Eli Lilly and Company?
The ticker symbol for Eli Lilly and Company is NYSE:LLY
Does Eli Lilly and Company pay dividends?
Yes, Eli Lilly and Company pays dividends. The last payment was $1.50, with an ex-dividend date on November 14, 2025
What sector is Eli Lilly and Company in?
Eli Lilly and Company is in the Healthcare sector
What industry is Eli Lilly and Company in?
Eli Lilly and Company is in the General Drug Manufacturers industry
What country is Eli Lilly and Company based in?
Eli Lilly and Company is headquartered in United States
When did Eli Lilly and Company go public?
Eli Lilly and Company initial public offering (IPO) was on June 1, 1972
Is Eli Lilly and Company in the S&P 500?
Yes, Eli Lilly and Company is included in the S&P 500 index
Is Eli Lilly and Company in the NASDAQ 100?
No, Eli Lilly and Company is not included in the NASDAQ 100 index
Is Eli Lilly and Company in the Dow Jones?
No, Eli Lilly and Company is not included in the Dow Jones index
When was Eli Lilly and Company last earnings report?
Eli Lilly and Company's most recent earnings report was on October 30, 2025
When does Eli Lilly and Company report earnings?
The next expected earnings date for Eli Lilly and Company is February 4, 2026
